Dual role of interferon-γ signalling pathway in sensitivity of pancreatic beta cells to immune destruction

被引:25
作者
Gysemans, CA
Pavlovic, D
Bouillon, R
Eizirik, DL
Mathieu, C
机构
[1] Katholieke Univ Leuven, Gasthuisberg O&N, LEGENDO, UZ, B-3000 Louvain, Belgium
[2] Free Univ Brussels, Ctr Diabet Res, Gene Express Unit, Brussels, Belgium
关键词
Type I diabetes; cytokines; interferon regulatory factor-1; interferon-gamma; signal transduction; islet destruction;
D O I
10.1007/s001250051662
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis. Disruption of the interferon-gamma (IFN-gamma) signalling pathway at the level of interferon regulatory factor-1 (IRF-1) protects islets against cytokine-incluced nitric oxide production and cell death in vitro. The aim of this study was to investigate the effects of a global disruption of IFN-gamma signalling, or a selective disruption of IRF-1, on beta-cell sensitivity to in vivo immune destruction. Methods. In a first set of experiments, IFN-gamma receptor knockout mice (IFN-gammaR(-/-)) and interferon regulatory factor-1 knockout mice (IRF-1(-/-)) were rendered diabetic by injections of 50 mg streptozotocin i.p. on 5 consecutive days (MLDSTZ). Results. Whereas no difference in sensitivity to MLDSTZ-induced diabetes could be observed between IFN-gammaR(-/-) mice and their 129/Sv/Ev controls (50 % vs 55 %, NS), there was an increased incidence of diabetes in IRF-1(-/-) mice (100% vs 67 % in C57B1/6 mice, p < 0.05). A similar increased sensitivity to immune destruction of IRF-1(-/-) islets was observed when these islets were used as allografts. Islet graft survival rate of IFN-<gamma>R-/- and 129/Sv/Ev islets, when transplanted in alloxan-diabetic BALB/c recipients. was comparable (12.0 +/- 1.9 days vs 12.9 +/- 2.3 da)is, NS). Allograft rejection, however, of IRF-1(-/-) islets by BALB/c recipients occurred more rapidly than following transplantation to their C57Bl/6 controls (9.1 +/- 2.0 days vs 13.1 +/- 1.5 days, p < 0.003. Conclusions/interpretation. These data indicate that IFN-<gamma> signal transduction at the beta-cell level is not essential for immune beta-cell destruction in vive. Moreover, disruption of the IRF-1 gene in pancreatic islets increases susceptibility to beta-cell killing, suggesting that IRF-1 might be necessary for the expression of putative beta-cell "defence and/or repair" genes.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 35 条
[1]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[2]   Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine [J].
Casteels, K ;
Waer, M ;
Laureys, J ;
Valckx, D ;
Depovere, J ;
Bouillon, R ;
Mathieu, C .
TRANSPLANTATION, 1998, 65 (09) :1225-1232
[3]   Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells [J].
Darville, MI ;
Eizirik, DL .
DIABETOLOGIA, 1998, 41 (09) :1101-1108
[4]   PREVENTION OF DIABETES IN NOD MICE TREATED WITH ANTIBODY TO MURINE IFN-GAMMA [J].
DEBRAYSACHS, M ;
CARNAUD, C ;
BOITARD, C ;
COHEN, H ;
GRESSER, I ;
BEDOSSA, P ;
BACH, JF .
JOURNAL OF AUTOIMMUNITY, 1991, 4 (02) :237-248
[5]   ENDOGENOUS NITRIC-OXIDE INDUCED BY INTERLEUKIN-1-BETA IN RAT ISLETS OF LANGERHANS AND HIT-T15 CELLS CAUSES SIGNIFICANT DNA-DAMAGE AS MEASURED BY THE COMET ASSAY [J].
DELANEY, CA ;
GREEN, MHL ;
LOWE, JE ;
GREEN, IC .
FEBS LETTERS, 1993, 333 (03) :291-295
[6]   Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells [J].
Delaney, CA ;
Pavlovic, D ;
Hoorens, A ;
Pipeleers, DG ;
Eizirik, DL .
ENDOCRINOLOGY, 1997, 138 (06) :2610-2614
[7]  
Eizirik DL, 1997, DIABETES METAB REV, V13, P293, DOI 10.1002/(SICI)1099-0895(199712)13:4<293::AID-DMR195>3.3.CO
[8]  
2-W
[9]  
ERIRIK DL, 1996, DIABETOLOGIA, V39, P875
[10]   Interferon-gamma-induced interferon regulatory factor-1 (IRF-1) expression in rodent and human islet cells precedes nitric oxide production [J].
Flodstrom, M ;
Eizirik, DL .
ENDOCRINOLOGY, 1997, 138 (07) :2747-2753